Estrogen receptors (ERs) regulate gene transcription by interacting with regulatory elements. Most information regarding how ER activates genes has come from studies using a small set of target genes or simple consensus sequences such as estrogen response element, activator protein 1, and Sp1 elements. However, these elements cannot explain the differences in gene regulation patterns and clinical effects observed with estradiol (E 2 ) and selective estrogen receptor modulators. To obtain a greater understanding of how E 2 and selective estrogen receptor modulators differentially regulate genes, it is necessary to investigate their action on a more comprehensive set of native regulatory elements derived from ER target genes. Here we used chromatin immunoprecipitationcloning and sequencing to isolate 173 regulatory elements associated with ER␣. Most elements were found in the introns (38%) and regions greater than 10 kb upstream of the transcription initiation site (38%); 24% of the elements were found in the proximal promoter region (<10 kb). Only 11% of the elements contained a classical estrogen response element; 23% of the elements did not have any known response elements, including one derived from the naked cuticle homolog gene, which was associated with the recruitment of p160 coactivators. Transfection studies found that 80% of the 173 elements were regulated by E 2 , raloxifene, or tamoxifen with ER␣ or ER␤. Tamoxifen was more effective than raloxifene at activating the elements with ER␣, whereas raloxifene was superior with ER␤. Our findings demonstrate that E 2 , tamoxifen, and raloxifene differentially regulate native ER-regulatory elements isolated by chromatin immunoprecipitation with ER␣ and ER␤. (Molecular Endocrinology 22: 287-303, 2008) D RUGS THAT INTERACT with estrogen receptors (ERs) are commonly used to treat numerous reproductive conditions. Estrogens are mainly used for contraception and to treat a variety of menopausal symptoms, such as hot flashes and urogenital atrophy. However, the use of estrogens for menopausal symptoms has been severely curtailed after the results of the Women's Health Initiative trial found that the risks of hormone therapy exceed the benefits (1). The selective estrogen receptor modulators (SERMs) differ from estrogens in that they exhibit both agonistic and antagonistic properties. Tamoxifen is the prototypic SERM that acts as an antagonist in the breast and an agonist in bone and uterus (2). Therefore, tamoxifen is used to treat and prevent ER-positive breast tumors (3). Raloxifene behaves similarly to tamoxifen in the breast and bone (4, 5) but does not elicit an agonistic action in the uterus (6). Raloxifene is hence approved for the prevention and treatment of osteoporosis. Although the SERMs have some exciting properties, a major limitation is that they do not prevent hot flashes. Furthermore, the results of clinical trials with SERMs are showing that both drugs can produce serious adverse effects (7). These observations clearly indicate that it is essential to develop a new generation of safer drugs that target ERs. To achieve this goal, a greater understanding of how estrogens and SERMs regulate genes that mediate their beneficial and adverse effects is needed.
Estrogen receptors (ERs) regulate gene transcription by interacting with regulatory elements. Most information regarding how ER activates genes has come from studies using a small set of target genes or simple consensus sequences such as estrogen response element, activator protein 1, and Sp1 elements. However, these elements cannot explain the differences in gene regulation patterns and clinical effects observed with estradiol (E 2 ) and selective estrogen receptor modulators. To obtain a greater understanding of how E 2 and selective estrogen receptor modulators differentially regulate genes, it is necessary to investigate their action on a more comprehensive set of native regulatory elements derived from ER target genes. Here we used chromatin immunoprecipitationcloning and sequencing to isolate 173 regulatory elements associated with ER␣. Most elements were found in the introns (38%) and regions greater than 10 kb upstream of the transcription initiation site (38%); 24% of the elements were found in the proximal promoter region (<10 kb). Only 11% of the elements contained a classical estrogen response element; 23% of the elements did not have any known response elements, including one derived from the naked cuticle homolog gene, which was associated with the recruitment of p160 coactivators. Transfection studies found that 80% of the 173 elements were regulated by E 2 , raloxifene, or tamoxifen with ER␣ or ER␤. Tamoxifen was more effective than raloxifene at activating the elements with ER␣, whereas raloxifene was superior with ER␤. Our findings demonstrate that E 2 , tamoxifen, and raloxifene differentially regulate native ER-regulatory elements isolated by chromatin immunoprecipitation with ER␣ and ER␤. (Molecular Endocrinology 22: 287-303, 2008) D RUGS THAT INTERACT with estrogen receptors (ERs) are commonly used to treat numerous reproductive conditions. Estrogens are mainly used for contraception and to treat a variety of menopausal symptoms, such as hot flashes and urogenital atrophy. However, the use of estrogens for menopausal symptoms has been severely curtailed after the results of the Women's Health Initiative trial found that the risks of hormone therapy exceed the benefits (1) . The selective estrogen receptor modulators (SERMs) differ from estrogens in that they exhibit both agonistic and antagonistic properties. Tamoxifen is the prototypic SERM that acts as an antagonist in the breast and an agonist in bone and uterus (2) . Therefore, tamoxifen is used to treat and prevent ER-positive breast tumors (3) . Raloxifene behaves similarly to tamoxifen in the breast and bone (4, 5) but does not elicit an agonistic action in the uterus (6) . Raloxifene is hence approved for the prevention and treatment of osteoporosis. Although the SERMs have some exciting properties, a major limitation is that they do not prevent hot flashes. Furthermore, the results of clinical trials with SERMs are showing that both drugs can produce serious adverse effects (7) . These observations clearly indicate that it is essential to develop a new generation of safer drugs that target ERs. To achieve this goal, a greater understanding of how estrogens and SERMs regulate genes that mediate their beneficial and adverse effects is needed. The nearest gene associated with the ER␣Ϫbinding element from the ChIP library was identified by the human genome. The presence of ERE, AP-1, Sp1, NFB, and FOXA1-binding sites in clones were determined by bioinformatics using programs described in Materials and Methods. The accession numbers were obtained from the National Center for Biotechnology Information database.
The execution of the biological effects of estrogens and SERMs is mediated by two ERs: ER␣ and ER␤. Once the ligand binds to these receptors, it induces a conformational change (8) that allows the receptor to interact with a regulatory element in target genes. Whereas the estrogen response element (ERE) is considered to be the major regulatory element in genes regulated by ERs (9), alternative elements, such as activator protein 1 (AP-1) (10) and Sp1 (11) , are required for estradiol (E 2 ) and SERMs to regulate the full spectrum of genes. When an estrogen-bound ER associates with a regulatory element, it recruits distinct classes of proteins, including p160s coactivators, mediator complex proteins, and cAMP response element-binding protein (CREB)-binding protein/p300, in a sequential and cyclical manner to activate gene transcription (12) (13) (14) . In contrast, SERMs act as antagonists by recruiting corepressor proteins, such as nuclear receptor corepressor, that block the expression of the target gene (15) . The mechanism of the agonist action that leads to transcriptional activation by SERMs is poorly understood but is thought to be mediated via the recruitment of coactivators to the activation function (AF)-1 domain of ERs (16, 17) .
Although the ERE and alternative elements are important mediators of ER regulation of genes, the pharmacology of E 2 and SERMs on target genes cannot be understood solely by the known regulatory elements (18) (19) (20) . For example, it is not yet known how E 2 distinctly regulates genes with ER␣ and ER␤ (18, 21, 22) and how some genes regulated by tamoxifen are different from those regulated by raloxifene (18, 23) . These observations indicate that in addition to the known regulatory elements, other types of elements exist in ER target genes. Identifying new regulatory elements in ER target genes is a critical step in the elucidation of how estrogens and SERMs induce the therapeutic and adverse effects observed in clinical trials. Previously, the standard way to identify ER-regulatory elements was to clone the promoter region and map the element with a series of deletion and point mutants upstream of a reporter gene. Recently, ER binding sites were identified by using a combination of chromatin immunoprecipitation (ChIP) and tiling arrays that contained chromosomes 21 and 22 (24) or the whole genome (25) . ChIP also has been combined with sequencing to identify ER elements in MCF-7 cells (26) . Here, we used a chromatin immunoprecipitation-cloning and sequencing (ChIP-CS) strategy to isolate genomewide ER response elements from target genes in U2OS bone cells. Our goal was to assess the functional properties of a large set of ER-binding elements in response to different ligands. We isolated and tested 173 ER-regulatory elements for regulation by E 2 , raloxifene, and tamoxifen with both ER␣ and ER␤.
RESULTS

ChIP-Cloning and Sequencing Identifies ER␣-Binding Elements
U2OS cells that express a stably transfected FLAG-ER␣ were treated for 2 h with E 2 and then were cross-linked with formaldehyde. After shearing the chromatin, the ER␣-bound DNA fragments were isolated using an antibody against the FLAG epitope. DNA fragments were then further purified with an antibody against ER␣. Isolated DNA fragments were cloned into plasmids, and 192 were randomly selected and sequenced. Bioinformatics was used to match the sequences in the ChIP-CS library to genes by performing a BLAST search against the human genome. Of the clones sequenced, 173 contained inserts, which ranged in size from 200-500 bp. The chromosomal identifier and sequence of the 173 elements is shown in supplemental Table 1 published as supplemental data on The Endocrine Society's Journals Online website at http://mend. endojournals.org. The location and name of each element relative to the nearest gene is shown in Tables 1 and 2 .
Many Elements Do Not Contain an ERE or Other Known ER-Regulatory Elements
We found that 38% of the regulatory elements were located in introns ( Table 1) ; 24% of the regulatory elements were found less than 10 kb upstream region of the transcription start site (TSS), whereas the remaining 38% of the elements were located beyond 10 kb of the TSS (Table 2) . A histogram shows the distance of the elements from the TSS (Fig. 1) . To explore whether our ChIP-CS library contains authentic regulatory elements, we searched ER-responsive gene databases as well as our microarray data (18) for known ER target genes. We found that 10% of the genes in our ChIP-CS library were reported to be activated by E 2 or SERMs (Tables 1  and 2 ).
Many Elements Do Not Contain an ERE or other Known ER-Regulatory Elements
We searched multiple databases, including TRANS-FAC and Dragon ERE finder, to identify potential regulatory elements in the ChIP-CS library. Only 11% of the inserts contained classical EREs (Tables 1 and 2) . AP-1, Sp1, FOXA1, or nuclear factor-B (NFB) sites were present in 41%, 18%, 24%, and 33% of the inserts, respectively (Tables 1 and 2) . Surprisingly, 23% of the inserts did not have an ERE or one of the other alternative elements. These data support our hypothesis that additional types of regulatory elements exist in ER target genes. The nearest gene associated with the ER␣Ϫbinding element from the ChIP library was identified by the human genome. The presence of ERE, AP-1, Sp1, NFB, and FOX1A binding sites in clones were determined by bioinformatics using programs described in Materials and Methods. The accession numbers were obtained from the National Center for Biotechnology Information database.
E 2 Recruits ER␣ and p160 Coactivators to Elements Derived from the ChIP Library in U2OS-ER␣ Cells
We selected elements from six genes to determine whether ER␣ binds to those elements in the native genes in U2OS-ER␣ cells. In these cells, the native ER␣ is driven by a tetracycline-inducible CMV promoter that allows for titration of the ERs to approximate physiological levels (18) . ChIP shows that E 2 recruited ER␣ to the cat eye syndrome chromosome region candidate 6 (CECR6), spermatogenesis associated 13 (SPATA13), naked cuticule homolog (NKD), lethal giant larvae homolog 2, (LLGL2), H19, imprinted maternally expressed untranslated mRNA (H19), and killer cell lectin-like receptor subfamily C (NKG2) genes (Fig. 2) . E 2 activates genes by recruiting p160 coactivators (14, 27) , steroid receptor coactivator (SRC)1, SRC2 (transcriptional intermediary factor 2, glucocorticoid receptor interacting protein 1, and nuclear receptor coactivator 2), and SRC3 (pCIP, receptor-associated coactivator 3, amplified in breast cancer 1, and activator of thyroid and retinoic acid receptor) to the AF-2 surface of ER (28) (29) (30) . Using ChIP, we examined whether E 2 recruits p160 coactivators to the six genes. E 2 produced a time-dependent recruitment of p160 coactivators to the six genes with maximal recruitment occurring at 1-2 h (Fig. 3) . However, distinct coactivators were recruited to the genes. All three coactivators were recruited to the CECR6 (Fig. 3A) and H19 (Fig. 3E ) genes, whereas SRC-2 and SRC-3 were recruited to NKD (Fig. 3C) and NKG2 (Fig. 3F ) genes. SRC-1 and SRC-2 were recruited to LLGL2 (Fig. 3D) , whereas only SRC-3 was recruited to the SPATA13 (Fig. 3B) gene.
E 2 Activates and Recruits ER␤ and p160 Coactivators to the CECR6 and NKD Genes in U2OS-ER␤ Cells
The regulation of CECR6 and NKD genes by E 2 was also examined in the U2OS-ER␤ cells. U2OS-ER␤ cells were treated for increasing time with E 2 , and the levels of CECR6 and NKD mRNA were measured by real-time PCR. E 2 produced a maximal activation of the CECR6 gene in 6 h and at 3 h with the NKD gene (Fig. 4, A and B ). The activation of the genes was associated with the recruitment of ER␤ to the genes (Fig. 4, C and D) . In contrast to the ER␣ cells, ChIP found that only SRC-2 was recruited by E 2 to the CECR6 (Fig. 4E ) gene, whereas SRC-1 and SRC-2 were recruited to the NKD (Fig. 4E ) gene in the U2OS-ER␤ cells. Maximal recruitment of the coactivators was observed after 2 h (Fig. 4, E and F ). These findings demonstrate that both ER␣ and ER␤ bind to the CECR6 and NKD elements, but they recruit different p160 coactivators with E 2 .
Tamoxifen Is More Effective at Regulating the Elements Than Raloxifene with ER␣, Whereas Raloxifene Is Superior with ER␤
The ChIP library represents a powerful set of regulatory elements to study the differential regulation by E 2 , tamoxifen, and raloxifene. The 173 elements were (Tables 1  and 2 ) were plotted on a histogram. The y-axis represents the number of the clones, whereas the x-axis represents the distance of the clone to the nearest TSS. ERα Binding (fold change)
ERα Binding (fold change)
Fig. 2. ER␣ Interacts with Elements from the ChIP-CS Library
Tetracycline-inducible U2OS-ER␣ cells were treated with 10 nM E 2 for 3 h, and ChIP was performed using antibodies to ER␣. Immunoprecipitated chromatin fragments were PCR amplified and quantitated by real-time PCR using primers for the CECR6, SPATA13, NKD, LLGL2, H19, and NKG2 elements. Cont, Control.
cloned upstream of the minimal thymidine kinase (tk) promoter and then transfected into wild-type U2OS cells with an ER␣ or ER␤ expression vector. Cells were then treated with E 2 , tamoxifen, or raloxifene, and luciferase activity was measured. We found that 80% of the elements were regulated by at least one of the ligands with ER␣ or ER␤ (Table 3 ). Many elements that were located outside the promoter region were regulated by the ligands (Table 3) . Several regulated elements were located more than 500 kb from the transcription initiation site of the nearest gene. We also found that different elements derived from the same gene were differentially regulated by E 2 , tamoxifen, and raloxifene (Table 3 , boldface entries). Some elements were differentially regulated by E 2 , tamoxifen, or raloxifene. Surprisingly, however, we found that even though the library was derived from cells expressing ER␣ and treated with E 2 , more elements were regulated by SERMs than E 2 . Moreover, E 2 , tamoxifen, and raloxifene activated more elements in the presence of ER␤ compared with ER␣ (Table 3 ). We also found that more elements were activated by tamoxifen, compared with raloxifene, in the presence of ER␣, whereas raloxifene was more effective than tamoxifen at activating the elements in the presence of ER␤ (Table 4) .
To compare the effects of the ligands on mRNA expression with the transfection results, we examined whether 35 genes randomly selected were regulated Protein Binding (fold change)
Fig. 3. E 2 Recruits p160 Coactivators to Genes from the ChIP-CS Library
Tetracycline-inducible U2OS-ER␣ cells were treated with 10 nM E 2 for increasing times, and ChIP was performed using antibodies to the p160 coactivators, SRC-1, SRC-2, or SRC-3. Immunoprecipitated chromatin fragments were PCR amplified and quantitated by real-time PCR using primers for the CECR6, SPATA13, NKD, LLGL2, H19, and NKG2 elements (panels A-F, respectively).
by E 2 and SERMs in the previously characterized, tetracycline-inducible U2OS-ER␣ cells (18) . Cells were treated for various times with E 2 , tamoxifen, or raloxifene, and mRNA levels were determined by quantitative real-time PCR (qPCR). Similar to the transfection assays, several genes were regulated only by tamoxifen or raloxifene, even though the library was derived from cells treated with E 2 . Of the 35 genes examined, several showed good correlation with transfection assays. A similar pattern of regulation with transfection assays and qPCR were found with the NKG2E, CECR6, and NKD genes ( Table 5 ). The EMI domain containing 2 and calbindin 2,29 kDa genes were activated with E 2 by qPCR, but E 2 did not activate the elements in transfection studies. In contrast, elements from the oligodendrocyte lineage transcription factor 2, fem-1 homolog b, protein tyrosine phosphatase, receptor type, M, and astrotactin genes were activated by SERMs in transfection assays, but were not activated by qPCR.
DISCUSSION
Microarray data from our laboratory (18) showed that E 2 and SERMs exhibit a complex pattern of gene The asterisk represents a significant difference from control (P Ͻ 0.05). ChIP assays were performed using antibodies to ER␤ (C and D) and the p160 coactivators, SRC-1, SRC-2, or SRC-3 (E and F). Immunoprecipitated chromatin fragments were PCR amplified and quantitated by real-time PCR using primers for the CECR6 (C and E) and NKD (D and F) elements. Cont, Control. Wild-type U2OS cells were transfected with the different elements from the ChIP library, located upstream of the minimal tk promoter, and an ER␣ or ER␤ expression vector. Cells were then treated with 10 nM E 2 , 1 M tamoxifen or 1 M raloxifene for 18 h and luciferase assays were performed. Boldface entries indicate different elements located adjacent to one gene.
Each number represents the mean of three measurements. The SEM was less than 10%. T, Tamoxifen; R, raloxifene.
regulation that cannot be explained by the pharmacology of known ER-responsive elements such as ERE, AP-1, and Sp1. These data raise the possibility that many ER target genes contain unknown regulatory elements. Whereas microarrays easily identify ER target genes (19, 21, 31) they do not provide any information on the location or nature of the regulatory elements in the target gene. Thus, new genome-wide approaches are essential to rapidly isolate regulatory elements in target genes to understand how E 2 and SERMs exert tissue-specific clinical effects and produce the complex gene expression profiles observed with microarrays. ChIP-chip is a powerful strategy that has been used to identify elements in target genes for ER␣ (25, (35) (36) (37) . This approach is valuable to identify and annotate different classes of ER elements and to identify transcription factors that interact with ER-binding sites (25) . Here we used a ChIP-CS strategy to rapidly isolate and characterize ER-regulatory elements. We isolated 173 ER-binding elements that were tested for functional activity in response to E 2 and SERMs with ER␣ and ER␤.
We found that most elements were derived from introns and regions beyond 10 kb of the TSS. Only 24% of the elements were found within 10 kb of the TSS. ChIP-chip studies also showed that many ERregulatory elements are located at a distance far from the TSS (24, 25) . It also has been shown that 63% of the glucocorticoid response elements are found beyond 10 kb of the TSS (39) . These results demonstrate that the proximal promoter region only contains a small subset of response elements for steroid receptors.
Only 11% of the genes derived from the ChIP-CS library had an ERE despite the use of a fairly low stringency for detection. Although the ERE is considered to be the major response element in target genes, these results suggest that most ER target genes are regulated by response elements other than the classical ERE. Of the elements in the ChIP-CS library, 41% contained an AP-1 site, whereas 18% of the genes contained Sp1 elements. The most surprising finding was that 23% of the clones from the ChIP library did not contain an ERE or any of the known alternative elements. However, our transfection studies showed that 70% of the elements without a classical ERE, AP-1, Sp1, FOXA1, or NFB element were regulated by E 2 or SERMs, demonstrating that many regulatory sequences from the ChIP library contain unknown elements. This notion was supported by the data showing that E 2 activated and recruited p160s coactivators to the NKD gene, which did not have any known regulatory element.
A major advantage of having numerous elements from the ChIP library is that they can be examined for activity with different ligands and ERs. Most of the 173 elements were regulated by E 2 , tamoxifen, or raloxifene with ER␣ or ER␤ using transfection assays, demonstrating that the library contained genuine regulatory elements. By testing a large number of elements, we were able to discover several surprising and interesting observations. We found that more elements were regulated by SERMs, even though ChIP was done with E 2 -treated cells. One explanation for this finding is that E 2 regulation might require other factors that are lost during shearing of the chromatin. Genome-wide tiling arrays showed that many ER-binding sites are associated with transcription factor elements, such as FOX1A, AP-1, Oct, and CCAAT enhancer binding protein, which are important for regulation by E 2 (25) . Our findings suggest that the E 2 -ER complex binds to the elements and is recognized by the ChIP antibody. However, some elements are probably functionally inactive because the ER is unable to interact with factors that are absent from the ChIP element and required for transcriptional regulation by E 2 . Alternatively, it is conceivable that the antibody, which we used for ChIP, selectively recognizes an ER conformation that is inactive or inhibitory when bound to E 2 . Other antibodies, such as the one used in the tiling arrays (25) , might recognize an ER conformation that is capable of detecting elements activated by E 2 . Finally, it is likely that some of the ER-binding sites might be silent in U2OS cells and do not function as regulatory elements in response to E 2 . Some of these inactive elements might be regulated by E 2 in other cell types.
Another important finding from the functional studies of the ChIP library was that the magnitude of activation of most elements by tamoxifen was greater with ER␣, whereas raloxifene was more effective at activating the elements in the presence of ER␤. The reason for the differences in activation with the two receptor subtypes is unclear. Tamoxifen binds equally to ER␣ and ER␤ (40) , whereas raloxifene binds with about 2-fold greater affinity to ER␤ than ER␣ (41) . These results demonstrate that differences in binding do not account for the difference in the activity of The numbers listed are for genes activated with the drug by at least 2-fold. For the genes listed for tamoxifen vs. raloxifene the magnitude of activation by one of the drugs ER␣ and ER␤ was at least 1.5-fold greater. (30) . The different conformations elicited by tamoxifen and raloxifene might lead to a differential binding of ERs to the regulatory elements or the recruitment of different coregulators by ER␣ and ER␤ at the elements. We previously showed that tamoxifen and raloxifene activate the NKG2E gene by recruiting different coactivators (42) . We also found that tamoxifen activated the CECR6 and NKD genes from the ChIP library by recruiting coactivators (data not shown). In contrast, raloxifene did not activate these genes or recruit coactivators. These results indicate that the SERMs produce different conformations in ER, which leads to the differential recruitment of coactivators. The observation that the agonist activity of SERMs is mediated by coactivators is consistent with the findings that coactivators can interact with the AF-1 in the A/B domain (16, 17) .
One of the more surprising findings was the lack of correlation between the gene expression data and transfection studies. Previous studies selected a few elements derived from ChIP to correlate gene expression with function in response to E 2 with transfection studies (25, 26) . To avoid any potential bias in selecting elements to examine, we cloned all 173 elements from the library upstream of tk-luciferase. Only a few of the 35 genes that were tested for expression data by PCR showed an exact correlation with transfection assays. There are several possible explanations for these findings. First, the element from the ChIP library was assigned to the nearest gene. However, it is possible that the element actually regulates one of the other three adjacent genes, rather than the nearest gene. Second, because of compact folding of chromatin, the regulatory element isolated from the ChIP library could actually be in close proximity to distant target genes. It is well recognized that enhancers can operate at far distances (43) . For example, the E2 enhancer region interacts with distant Sp1 transcription factors by forming stable DNA loops that can be visualized by electron microscopy (44) . These findings suggest that the elements from the ChIP library might bypass adjacent genes and cause regulation of distant ER target genes. Third, it is likely that some regulatory elements function differently in the context of native genes. Genes also contain silencers, which are elements that bind repressor proteins that repress the activation of the gene. Thus, some elements from the ChIP library that are functional when isolated and inserted upstream of the tk promoter might be silenced by other factors that interact with the native gene. This might be an important mechanism for tissue-specific gene expression if the factors are differentially expressed in different cell types. The results from our qPCR and luciferase data suggest that it is highly probable that the element actually regulates the assigned gene only when there is good correlation between ER binding by ChIP, mRNA expression, and transfection data.
Our results suggest that many ER target genes are regulated by elements other than ERE, AP-1, Sp1, FOXA1, and NFB. We performed extensive bioinformatic analysis of the elements to identify other motifs that might be involved in regulation by ER. However, we were unable to discover any new motifs present in the majority of elements. This might be due to the fact that the ChIP library contained too few genes to detect new motifs. However, our detailed analysis of one element from the ChIP library (42) suggests it will be extremely difficult to detect single motifs even with many more elements. We found that the NKG2E gene contains a complex composite element (45) , which comprises four elements (AP-1, heat shock factor-2, CCAAT enhancer binding protein-␤, and a variant ERE) that cooperate to regulate the gene by E 2 and SERMs (42) . The results with the NKG2E-regulatory element and our ChIP library, showing that different elements, even within the same gene, are differentially regulated by E 2 , tamoxifen, and raloxifene, suggest that many ER targets are regulated by a combination of cooperative elements rather than a single element, such as ERE, AP-1, and Sp1. The tiling arrays suggest that ER cooperates with a preferred set of transcription factors (25) . However, our data suggest that many different combinations of factors interact with ER, because we were unable detect any consistent combination of elements in the ChIP library. Furthermore, it is also likely that the factors with which ER interacts to regulate genes varies in different cell types. This notion is consistent with our observation that some of the ChIP library elements were regulated differently by E 2 and SERMs in various cell types (data not shown).
The data from our ChIP library and tiling arrays clearly indicate that most ER target genes are regulated by ER interacting with a combination of multiple different transcription factors, rather than binding exclusively to an ERE. Identifying combinatorial regulatory elements will likely require detail mapping of many elements with functional studies. The isolation of regulatory elements from native genes with techniques such as ChIP-CS is a major step toward understanding how ER␣ and ER␤ regulate different genes in response to diverse ligands, and how E 2 and SERMs produce unique clinical effects. However, our findings also suggest that whereas ChIPchip and ChIP-CS can identify ER-binding sites and regulatory elements, it can be difficult to identify the exact gene that is regulated by the element, even when the element is in close proximity or within a gene. A major challenge will be to develop strategies to accurately assign the proper gene that is regulated by the elements identified with tiling arrays or sequencing.
MATERIALS AND METHODS
Preparation of Stable Cell Lines
U2OS cells stably expressing Flag-tagged ER␣ were prepared by transfecting wild-type U2OS cells with pcDNA 6/V5-His vector containing Flag-ER␣. Cells were selected and maintained using 10 g/ml blasticidin. Tetracycline-inducible U2OS-ER␣ and U2OS-ER␤ cells were prepared, characterized, and maintained as previously described (18) .
Chromatin Immunoprecipitation Cloning and Sequencing (ChIP-CS)
U2OS-Flag-ER␣ cells were treated with 10 nM E 2 for 2 h and then cross-linked, washed, collected, and lysed as previously described (18, 46) . Nuclei were then resuspended in FLAG protein immunoprecipitation buffer (50 mM Tris HCl, pH 7;4, 150 mM NaCl; 1 mM EDTA; 1% Triton X-100) and sonicated. The supernatant fraction was collected and incubated with anti-flag M2 agarose beads (Sigma-Aldrich, St. Louis, MO) for 2 h at 4 C. After the beads were washed (0.05 M Tris HCl, pH 7.4; 0.15 M NaCl), the proteins were eluted using 150 ng/l 3X FLAG peptide (Sigma-Aldrich) in 0.05 M Tris HCl (pH 7.4)-0.15 M NaCl. Eluted proteins were then incubated with anti-ER␣ (DAKO Corp., Carpinteria, CA) coated magnetic beads (Dynabeads M-280) for 2 h. Beads were washed with PBS containing 1% BSA, and cross-linking of DNA/proteins was reversed with 1% sodium dodecyl sulfate-0.1 M NaHCO 3 at 65 C. DNA fragments were purified, (QIAquick PCR Purification Kit; QIAGEN, Chatsworth, CA), blunt ended, and cloned, and plasmids were isolated and sequenced (Lark Technologies, Houston, TX).
Plasmids, Transfections, and Luciferase Assays
Inserts from the plasmids were cloned upstream of Ϫ32 to ϩ45 tk-luciferase. Transfections of the various vectors into U2OS cells were carried out by electroporation (47) . Cells were assayed for luciferase activity according to manufacturer's protocol (Promega Corp., Madison, WI).
RNA Extraction and Quantitative Real-Time PCR
Total RNA was extracted and then treated with DNAse using the Aurum Total RNA Mini Kit (Bio-Rad Laboratories, Hercules, CA). Reverse transcription reactions were performed using the iScript cDNA Synthesis Kit with 1 g of total RNA as previously described (48) . qPCR was performed with a Bio-Rad iCycler Thermal Cycler System using iQ SYBR Green Supermix (Bio-Rad). Mean Ϯ SEM was calculated using Prism curve-fitting program (GraphPad Software, Inc., San Diego, CA). The primers used for qPCR are listed in supplemental Table 2 .
Chromatin Immunoprecipitation (ChIP)
After treatments, cells were cross-linked, washed, collected, and lysed as described above. Immunoprecipitations were performed overnight at 4 C with anti-ER␣ (HC-20), (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-SRC-1 (1135) (Upstate Biotechnology, Inc., Lake Placid, NY), anti-SRC-2 (ab9261), and anti-SRC-3 (ab2782), (Abcam, Cambridge, MA). DNA fragments were purified (QIAquick PCR Purification Kit; QIAGEN) and PCR amplified. The primers used for ChIP are listed in supplemental Table 2 .
Bioinformatics
To find putative ER target genes, the 192 sequences from the ChIP library were mapped to the human genome (HG 35.1 reference assembly) using BLAST with a threshold 1e-30. A set of 173 sequences that had significant hits was returned with four genes each: the nearest gene on each strand in each of the forward and reverse directions. Putative target genes were selected according to their positions relative to the hits. The computational programs MATCH (49) and Dragon ERE finder (50) were used to scan the 173 sequences for putative EREs, AP-1, SP1, foxA1, and NFB. These two programs search for sites by scoring their similarity to experimentally verified EREs. When applying MATCH, two ERE position weight matrices, one from the TRANSFAC (51) database (matrix ID: V $ER_Q6), and the other one built from 25 EREs known in literature (52) were used. In these cases the threshold for declaring a putative ERE was set to minimize the sum of the false positives and false negatives. When applying the Dragon ERE finder, the default threshold for obtaining 0.83 sensitivity was used.
